[Research progress on selective immunoproteasome inhibitors].

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• Immunoproteasome is linked to various diseases, including hematologic malignancies, inflammatory conditions, autoimmune disorders, and central nervous system diseases.
• Overexpression of immunoproteasome is a common feature across these associated pathologies.
• Immunoproteasome inhibitors show therapeutic potential by modulating T lymphocyte activity and reducing disease-associated factors.

Purpose of the Study:

• To review the structure, functions, and disease associations of immunoproteasome.
• To highlight the current status, structure, and activity of selective immunoproteasome inhibitors.
• To emphasize the importance of selectivity and potency in developing effective immunoproteasome inhibitors.

Main Methods:

• Literature review of immunoproteasome structure and function.
• Analysis of disease associations with immunoproteasome.
• Survey of selective immunoproteasome inhibitors, their structures, and activities.

Main Results:

• Immunoproteasome plays a role in diverse pathologies, with its overexpression being a consistent finding.
• Inhibitors can mitigate disease by reducing immunoproteasome expression and T lymphocyte activity.
• High selectivity and potent activity against proteasome subunits are crucial for developing safe and effective inhibitors.

Conclusions:

• Selective immunoproteasome inhibitors represent a promising therapeutic strategy for a range of diseases.
• Further research into the structure-activity relationships of these inhibitors is warranted.
• Targeting immunoproteasome offers a pathway to manage complex diseases with potentially fewer side effects.